The influence of atorvastatin on parameters of inflammation left ventricular function, hospitalizations and mortality in patients with dilated cardiomyopathy - 5-year follow-up

Lipids in Health and Disease

Volumn 12, Issue 1, 2013, Pages

  Bielecka Dabrowa, Agata ^a   Mikhailidis, Dimitri P ^b   Rizzo, Manfredi ^c,d   Von Haehling, Stephan ^e   Rysz, Jacek ^a   Banach, Maciej ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY OF PALERMO   (Italy)

^d Euro Mediterranean Institute of Science and Technology   (Italy)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Atorvastatin; Dilated cardiomyopathy; Heart failure; Inflammation

Indexed keywords

ACENOCOUMAROL; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMIODARONE; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INTERLEUKIN 6; LOOP DIURETIC AGENT; ORAL ANTIDIABETIC AGENT; SARTAN DERIVATIVE; SPIRONOLACTONE; TUMOR NECROSIS FACTOR ALPHA; URIC ACID; WARFARIN; CYTOKINE; HEPTANOIC ACID DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PYRROLE DERIVATIVE;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR MORTALITY; CARDITIS; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CYTOKINE RELEASE; DOPPLER ECHOCARDIOGRAPHY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FILLING; HEART LEFT VENTRICLE FUNCTION; HEMODYNAMIC PARAMETERS; HOSPITALIZATION; HUMAN; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MYOCARDIAL PERFORMANCE INDEX; MYOCARDITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PROBABILITY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; SYSTOLIC BLOOD PRESSURE; BLOOD; CARDIOMYOPATHY, DILATED; DRUG EFFECTS; INFLAMMATION; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOMYOPATHY, DILATED; CYTOKINES; FEMALE; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HOSPITALIZATION; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PYRROLES; URIC ACID; VENTRICULAR FUNCTION, LEFT;

EID: 84875866401     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-12-47     Document Type: Article

References (62)

1. The classification concept of the ESC Working Group on myocardial and pericardial diseases for dilated cardiomyopathy. Kaski JP, Elliott P, ESC Working Group, Herz 2007 32 6 446 451 10.1007/s00059-007-3045-5 17882369
2. Statins and dilated cardiomyopathy: do we have enough data? Bielecka-Dabrowa A, Mikhailidis DP, Hannam S, Aronow WS, Rysz J, Banach M, Expert Opin Investig Drugs 2011 20 3 315 323 10.1517/13543784.2011.550570 21210757
3. BMBF-Heart Failure Network. Inflammatory dilated cardiomyopathy (DCMI). Maisch B, Richter A, Sandmöller A, Portig I, Pankuweit S, Herz 2005 30 6 535 544 10.1007/s00059-005-2730-5 16170686
4. Proinflammatory cytokines in cardiovascular diseases as potential therapeutic target. Bielecka-Dabrowa A, Wierzbicka M, Goch JH, Wiad Lek 2007 60 9-10 433 438 18350717
5. Heart failure biomarkers in patients with dilated cardiomyopathy. Bielecka-Dabrowa A, Von Haehling S, Aronow WS, Ahmed MI, Rysz J, Banach M, Int J Cardiol 2013 10.1016/j.ijcard.2013.01.157
6. An update on biomarkers of heart failure in hypertensive patients. Gluba A, Bielecka-Dabrowa A, Mikhailidis DP, Wong ND, Franklin SS, Rysz J, Banach M, J Hypertens 2012 30 9 1681 1689 10.1097/HJH.0b013e3283569a9c 22828089
7. In vitro inhibitory effects of atorvastatin on cardiac fibroblasts: implications for ventricular remodeling. Martin J, Denver R, Bailey M, Krum H, Clin Exp Pharmacol Physiol 2005 32 697 701 10.1111/j.1440-1681.2005.04256.x 16173924
8. The relationship between high-density lipoprotein, bacterial lipopolysaccharide, and tumour necrosis factor-α in patients with acute decompensated heart failure. Zimmermann AV, Doehner W, Vaz Pérez A, Schmidt H, Volk HD, Anker SD, Rauchhaus M, Arch Med Sci 2008 4 380 385
9. Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells. Haendeler J, Hoffmann J, Zeiher AM, Dimmeler S, Circulation 2004 110 851 861
10. Neutrophil superoxide anion generation during atorvastatin and fluvastatin therapy used in coronary heart disease primary prevention. Kowalski J, Barylski M, Banach M, Grycewicz J, Irzmański R, Pawlicki L, J Cardiovasc Pharmacol 2006 48 4 143 147 10.1097/01.fjc.0000246150.52382.07 17086091
11. Why did high-dose rosuvastatin not improve cardiac remodeling in chronic heart failure? Mechanistic insights from the UNIVERSE study. Ashton E, Windebank E, Skiba M, Reid C, Schneider H, Rosenfeldt F, Tonkin A, Krum H, Int J Cardiol 2011 146 3 404 407 10.1016/j.ijcard.2009.12.028 20085851
12. and for the CORONA Group. Rosuvastatin in older patients with systolic heart failure. Kjekshus J, Apetrei A, Barrios V, N Engl J Med 2007 357 2248 2261 10.1056/NEJMoa0706201 17984166
13. Gissi-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Tavazzi L, Maggioni AP, Marchioli R, Lancet 2008 372 1231 1239 10.1016/S0140-6736(08)61240-4 18757089
14. Atorvastatin therapy may reduce the incidence of sudden cardiac death in patients with advanced chronic heart failure. Vrtovec B, Okrajsek R, Golicnik A, Ferjan M, Starc V, Schlegel TT, J Cardiac Fail 2008 14 140 144 10.1016/j.cardfail.2007.10.013
15. Statin therapy blunts inflammatory activation and improves prognosis and left ventricular performance assessed by Tissue Doppler Imaging in subjects with chronic ischemic heart failure: results from the Daunia Heart Failure Registry. Correale M, Brunetti ND, Totaro A, Montrone D, Russo AR, Fanigliulo AM, Ieva R, Di Biase M, Clinics (Sao Paulo) 2011 66 5 777 784
16. The influence of atorvastatin on parameters of inflammation and function of the left ventricle in patients with dilated cardiomyopathy. Bielecka-Dabrowa A, Goch JH, Mikhailidis DP, Rysz J, Maciejewski M, Banach M, Med Sci Monit 2009 15 12 S12 MS23 19946241
17. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Dickens K, Cohen-Solal A, Filippatos G, Eur J Heart Fail 2008 10 933 989 10.1016/j.ejheart.2008.08.005 18826876
18. Classification of the cardiomyopathies: a position statement from the European society of cardiology working group on myocardial and pericardial diseases. Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, Dubourg O, Kühl U, Maisch B, McKenna WJ, Monserrat L, Pankuweit S, Rapezzi C, Seferovic P, Tavazzi L, Keren A, Eur Heart J 2008 29 270 276 17916581
19. New methods in laboratory diagnostics of dilated cardiomyopathy. Bielecka-Dabrowa A, Wierzbicka M, Dabrowa M, Goch A, Cardiol J 2008 15 4 388 395 18698552
20. Faigenbaum H, Armstrong WF, Ryan T, Echokardiografia Faigenbauma" Wydanie polskie Warszawa: Medipage 2006 238 239 in Polish 22006607
21. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure2012 of the European Society of Cardiology, Eur Heart J 2012 33 14 1787 1847 22611136
22. A new method for estimating left ventricular dP/dT by continuous wale Doppler-echocardiography. Validation studies at cardiac catheterization. Bargiggia GS, Bertucci C, Recusani F, Circulation 1989 80 1287 1292 10.1161/01.CIR.80.5.1287 2805264
23. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Wassmann S, Laufs U, Baumer AT, Mol Pharmacol 2001 59 646 654 11179461
24. Potential role of HMG CoA reductase inhibitor on oxidative stress induced by advanced glycation endproducts in vascular smooth muscle cells of diabetic vasculopathy. Yoon SJ, Yoon YW, Lee BK, Exp Mol Med 2009 41 802 811 10.3858/emm.2009.41.11.086 19641377
25. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Laufs U, La Fata V, Plutzky J, Circulation 1998 97 1129 1135 10.1161/01.CIR.97.12.1129 9537338
26. Effects of atorvastatin on reactive hyperaemia and the thrombosis-fibrinolysis system in patients with heart failure. Tousoulis D, Antoniades C, Bosinakou E, Heart 2005 91 27 31 10.1136/hrt.2003.027110 15604328
27. Time for new indications for statins? Banach M, Mikhailidis DP, Kjeldsen SE, Rysz J, Med Sci Monit 2009 15 12 S1 MS5 19946240
28. Immunological aspects of the statins' function in patients with heart failure: a report from the Annual Conference of ESC-Heart Failure 2005. Banach M, Drozdz J, Okonski P, Rysz J, Cell Mol Immunol 2005 2 6 433 437 16426493
29. Metabolic, functional, and hemodynamic staging for CHF? Anker SD, Coats AJS, Lancet 1996 348 1530 10.1016/S0140-6736(05)66163-6 8950874
30. Uric acid and Survival in Chronic Heart Failure: Validation and Application in Metabolic, Functional, and Hemodynamic Staging. Anker SD, Doehner W, Rauchhaus M, Circulation 2003 107 1991 1997 10.1161/01.CIR.0000065637.10517. A0 12707250
31. Serum uric acid and cardiovascular disease. Iliesiu A, Campeanu A, Dusceac D, J Clin Med 2010 5 3 186 192
32. The paradoxical relationship between serum acid uric and cardiovascular disease. Lippi G, Mantagna M, Franchini M, Clin Chim Acta 2008 392 1 7 10.1016/j.cca.2008.02.024 18348869
33. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Kanellis J, Kang DH, Semin Nephrol 2005 25 39 42 10.1016/j.semnephrol.2004.09.007 15660333
34. Uric acid in chronic heart failure: a marker of chronic inflammation. Leyva F, Anker SD, Godsland IF, Teixeira M, Hellewell PG, Kox WJ, Poole-Wilson PA, Coats AJ, Eur Heart J 1998 19 1814 1822 10.1053/euhj.1998.1188 9886724
35. Uric Acid as prognostic marker in advanced nonischemic dilated cardiomyopathy: comparison with N-terminal pro B-type natriuretic peptide level. Kim H, Shin HW, Son J, Yoon HJ, Park HS, Cho YK, Han CD, Nam CW, Hur SH, Kim YN, Kim KB, Congest Heart Fail 2010 16 4 153 158 10.1111/j.1751-7133.2010.00144. x 20662867
36. Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels. Wojnicz R, Wilczek K, Nowalany-Kozielska E, Szyguła-Jurkiewicz B, Nowak J, Poloński L, Dyrbuś K, Badziński A, Mercik G, Zembala M, Wodniecki J, Rozek MM, Am J Cardiol 2006 97 6 899 904 10.1016/j.amjcard.2005.09. 142 16516598
37. The effects of short term statin treatment on left ventricular function and inflammatory markers in patients with chronic heart failure. Gurguna C, Ildizli M, Yavuzgil O, Int J Cardiol 2008 123 102 107 10.1016/j.ijcard.2006.11. 152 17320212
38. Statin therapy is associated with improved survival in ischemic and nonischemic heart failure. Horwich TB, MacLellan WR, Fonarow GC, J Am Coll Cardiol 2004 43 642 648 10.1016/j.jacc.2003.07.049 14975476
39. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. Sola S, Mir MQ, Lerakis S, J Am Coll Cardiol 2006 47 332 337 10.1016/j.jacc.2005.06.088 16412856
40. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Node K, Fujita M, Kitakaze M, Circulation 2003 108 839 843 10.1161/01.CIR.0000084539.58092.DE 12885745
41. Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone following high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level. Bleske BE, Nicklas JM, Bard RL, J Am Coll Cardiol 2006 47 338 341 10.1016/j.jacc.2005.06.087 16412857
42. Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure. Krum H, Ashton E, Reid C, J Card Fail 2007 13 1 7 10.1016/j.cardfail. 2006.09.008 17338996
43. Statin therapy and clinical outcomes in myocardial infarction patients complicated by acute heart failure: insights from the EPHESUS trial. Dobre D, Rossignol P, Murin J, Parkhomenko A, Lamiral Z, Krum H, Van Veldhuisen DJ, Pitt B, Zannad F, Eur J Heart Fail 2013 15 2 221 227 10.1093/eurjhf/hfs128 22872593
44. Impact of baseline systolic blood pressure on long-term outcomes in patients with advanced chronic systolic heart failure (insights from the BEST trial). Desai RV, Banach M, Ahmed MI, Mujib M, Aban I, Love TE, White M, Fonarow G, Deedwania P, Aronow WS, Ahmed A, Am J Cardiol 2010 106 2 221 227 10.1016/j.amjcard.2010.02.032 20599007
45. Effect of statin therapy on survival in patients with nonischemic dilated cardiomyopathy (from the Beta- blocker Evaluation of Survival Trial [BEST]). Domanski M, Coady S, Fleg J, Am J Cardiol 2007 99 1448 1450 10.1016/j.amjcard. 2006.12.080 17493477
46. Idiopathic dilated cardiomyopathy: analysis of 152 necropsy patients. Roberts WC, Siegel RJ, McManus BM, Am J Cardiol 1987 60 1340 1355 10.1016/0002-9149(87)90618-7 3687784
47. Lipid lowering drugs and recurrences of life-threatening ventricular arrhythmias in high-risk patients. De Sutter J, Tavernier R, De Buyzere M, J Am Coll Cardiol 2000 36 766 772 10.1016/S0735-1097(00)00787-7 10987597
48. The effect of early and intensive statin therapy on ventricular premature beat or non-sustained ventricular tachycardia in patients with acute coronary syndrome. Xian-zhi H, Sheng-hua Z, Xin-hong W, Cardiol J 2010 17 4 381 385 20690094
49. Reduction in Life-Threatening Ventricular Tachyarrhythmias in Statin-Treated Patients With Nonischemic Cardiomyopathy Enrolled in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy). Buber J, Goldenberg I, Moss AJ, J Am Coll Cardiol 2012 60 8 749 755 10.1016/j.jacc.2012.03.041 22703927
50. Rosuvastatin in older patients with systolic heart failure. Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JG, Cornel JH, N Engl J Med 2007 357 2248 2261 10.1056/NEJMoa0706201 17984166
51. Effects of atorvastatin on vascular intimal hyperplasia: an experimental rodent model. Aydin U, Ugurlucan M, Gungor F, Ziyade S, Inan B, Banach M, Kalko Y, Yasar T, Angiology 2009 60 3 370 377 10.1177/0003319708321102 18796450
52. Effect of atorvastatin in patients with chronic heart failure-insights from randomized clinical trials. Xu M, Yuan G, Wei F, Arch Med Sci 2010 6 6 866 873 22427759
53. Simvastatin therapy normalizes sympathetic neural control in experimental heart failure: Roles of angiotensin II type 1 receptors and NAD(P)H oxidase. Gao L, Wang W, Li YL, Schultz HD, Liu D, Cornish KG, Circulation 2005 112 1763 1770 10.1161/CIRCULATIONAHA.105.552174 16157767
54. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, N Engl J Med 1984 311 819 823 10.1056/NEJM198409273111303 6382011
55. Effect of Atorvastatin vs. Rosuvastatin on Cardiac Sympathetic Nerve Activity in Non-Diabetic Patients With Dilated Cardiomyopathy. Tsutamoto T, Sakai H, Ibe K, Yamaji M, Kawahara C, Nakae I, Fujii M, Yamamoto T, Horie M, Circ J 2011 75 2160 2166 10.1253/circj.CJ-11-0222 21737951
56. Plasma oxidized low-density lipoprotein as a prognostic predictor in patients with chronic congestive heart failure. Tsutsui T, Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, J Am Coll Cardiol 2002 39 957 962 10.1016/S0735-1097(02)01721-7 11897436
57. Sympathoinhibitory effect of statins in chronic heart failure. Gomes ME, Lenders JW, Bellersen L, Verheugt FW, Smits P, Tack CJ, Clin Auton Res 2010 20 73 78 10.1007/s10286-009-0041-2 19960360
58. Sympathoinhibition by atorvastatin in hypertensive patients. Gomes ME, Tack CJ, Verheugt FW, Smits P, Lenders JW, Circ J 2010 74 2622 2626 10.1253/circj.CJ-10-0427 20953062
59. Active metabolite of atorvastatin inhibits membrane cholesterol domain formation by an antioxidant mechanism. Mason RP, Walter MF, Day CA, Jacob RF, J Biol Chem 2006 281 9337 9345 16464853
60. Influence of co-existing atrial fibrillation on the efficacy of atorvastatin treatment in patients with dilated cardiomyopathy: a pilot study. Bielecka-Dabrowa A, Goch JH, Rysz J, Maciejewski M, Desai R, Aronow WS, Banach M, Lipids Health Dis 2010 9 21 10.1186/1476-511X-9-21 20178563
61. Lipids, blood pressure, kidney-what was new in 2011? Barylski M, Małyszko J, Rysz J, Myśliwiec M, Banach M, Arch Med Sci 2011 7 6 1055 1066 22328891
62. Effect of statin therapy on mortality in patients with non-ischemic dilated cardiomyopathy. Li X, Liu XP, Liu XH, Du X, Kang JP, Lü Q, Wang HY, Xu X, Liang C, Yan Q, Lei T, Geng LL, Liu BQ, Ma CS, Zhonghua Yi Xue Za Zhi 2010 90 28 1974 1977 20979862